Literature DB >> 35381199

LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.

Chamutal Gur1, Shuang-Yin Wang2, Fadi Sheban3, Mor Zada3, Baoguo Li3, Fadi Kharouf4, Hagit Peleg4, Suhail Aamar4, Adam Yalin3, Daniel Kirschenbaum3, Yolanda Braun-Moscovici5, Diego Adhemar Jaitin3, Tomer Meir-Salame6, Efrat Hagai6, Bjørt K Kragesteen3, Batia Avni7, Sigal Grisariu7, Chamutal Bornstein3, Shir Shlomi-Loubaton3, Eyal David3, Rony Shreberk-Hassidim8, Vered Molho-Pessach8, Dalit Amar9, Tomer Tzur9, Rottem Kuint10, Moshe Gross11, Oren Barboy3, Adi Moshe3, Liat Fellus-Alyagor12, Dana Hirsch12, Yoseph Addadi13, Shlomit Erenfeld7, Moshe Biton14, Tehila Tzemach4, Anat Elazary4, Yaakov Naparstek4, Reut Tzemach15, Assaf Weiner3, Amir Giladi3, Alexandra Balbir-Gurman5, Ido Amit16.   

Abstract

Systemic sclerosis (scleroderma, SSc) is an incurable autoimmune disease with high morbidity and mortality rates. Here, we conducted a population-scale single-cell genomic analysis of skin and blood samples of 56 healthy controls and 97 SSc patients at different stages of the disease. We found immune compartment dysfunction only in a specific subtype of diffuse SSc patients but global dysregulation of the stromal compartment, particularly in a previously undefined subset of LGR5+-scleroderma-associated fibroblasts (ScAFs). ScAFs are perturbed morphologically and molecularly in SSc patients. Single-cell multiome profiling of stromal cells revealed ScAF-specific markers, pathways, regulatory elements, and transcription factors underlining disease development. Systematic analysis of these molecular features with clinical metadata associates specific ScAF targets with disease pathogenesis and SSc clinical traits. Our high-resolution atlas of the sclerodermatous skin spectrum will enable a paradigm shift in the understanding of SSc disease and facilitate the development of biomarkers and therapeutic strategies.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOS; GVHD; LGR5; TWIST1; autoimmune; fibroblast; fibrosis; skin; systemic sclerosis

Mesh:

Substances:

Year:  2022        PMID: 35381199      PMCID: PMC7612792          DOI: 10.1016/j.cell.2022.03.011

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  55 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 2.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

3.  SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin.

Authors:  Tracy Tabib; Christina Morse; Ting Wang; Wei Chen; Robert Lafyatis
Journal:  J Invest Dermatol       Date:  2017-12-06       Impact factor: 8.551

4.  Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.

Authors:  Eleanor Valenzi; Melissa Bulik; Tracy Tabib; Christina Morse; John Sembrat; Humberto Trejo Bittar; Mauricio Rojas; Robert Lafyatis
Journal:  Ann Rheum Dis       Date:  2019-08-12       Impact factor: 19.103

Review 5.  The roles of dermal white adipose tissue loss in scleroderma skin fibrosis.

Authors:  Roberta G Marangoni; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2017-11       Impact factor: 5.006

6.  Human Dermal Fibroblast Subpopulations Are Conserved across Single-Cell RNA Sequencing Studies.

Authors:  Alex M Ascensión; Sandra Fuertes-Álvarez; Olga Ibañez-Solé; Ander Izeta; Marcos J Araúzo-Bravo
Journal:  J Invest Dermatol       Date:  2020-12-30       Impact factor: 8.551

7.  CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis.

Authors:  Alain Lescoat; Valérie Lecureur; Mikael Roussel; Béatrice Ly Sunnaram; Alice Ballerie; Guillaume Coiffier; Stéphane Jouneau; Olivier Fardel; Thierry Fest; Patrick Jégo
Journal:  Clin Rheumatol       Date:  2017-03-14       Impact factor: 2.980

8.  2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Ann Rheum Dis       Date:  2013-11       Impact factor: 19.103

9.  Single-cell chromatin state analysis with Signac.

Authors:  Tim Stuart; Avi Srivastava; Shaista Madad; Caleb A Lareau; Rahul Satija
Journal:  Nat Methods       Date:  2021-11-01       Impact factor: 47.990

10.  Lgr5+ telocytes are a signaling source at the intestinal villus tip.

Authors:  Keren Bahar Halpern; Hassan Massalha; Rachel K Zwick; Andreas E Moor; David Castillo-Azofeifa; Milena Rozenberg; Lydia Farack; Adi Egozi; Dan R Miller; Inna Averbukh; Yotam Harnik; Noa Weinberg-Corem; Frederic J de Sauvage; Ido Amit; Ophir D Klein; Michal Shoshkes-Carmel; Shalev Itzkovitz
Journal:  Nat Commun       Date:  2020-04-22       Impact factor: 14.919

View more
  2 in total

1.  Ablating Lgr5-expressing prostatic stromal cells activates the ERK-mediated mechanosensory signaling and disrupts prostate tissue homeostasis.

Authors:  Xing Wei; Li Zhang; Yiqun Zhang; Cody Cooper; Chris Brewer; Chia-Feng Tsai; Yi-Ting Wang; Micah Glaz; Hunter B Wessells; Jianwen Que; Mark A Titus; Vincenzino Cirulli; Adam Glaser; Tao Liu; Nicholas P Reder; Chad J Creighton; Li Xin
Journal:  Cell Rep       Date:  2022-09-06       Impact factor: 9.995

2.  Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.

Authors:  Dinesh Khanna; Cristina Padilla; Lam C Tsoi; Vivek Nagaraja; Puja P Khanna; Tracy Tabib; J Michelle Kahlenberg; Amber Young; Suiyuan Huang; Johann E Gudjonsson; David A Fox; Robert Lafyatis
Journal:  JCI Insight       Date:  2022-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.